integrin antagonists (3-Dimensional Pharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameintegrin antagonists (3-Dimensional Pharmaceuticals)
Drug Alias Namealpha-v/beta-5 antagonists (3-Dimensional Pharmaceuticals)alpha-v/beta-3 antagonists (3-Dimensional Pharmaceuticals)3DP-3360363PD-2293003DP-229300 +[8] 
ClassificationSmall molecules
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonistsAngiogenesis inhibitors
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsAngiogenesis disorderCoronary RestenosisDiabetic Retinopathy +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator Companies3-Dimensional Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies3-Dimensional Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAngiogenesis disorderCoronary RestenosisDiabetic Retinopathy +[5] 

Other Information

ATC CodeN/A
Related LinksN/A